Fennec Pharmaceuticals 2023 Corporate Presentation

Fennec Pharmaceuticals is a commercial-stage biotechnology company focused on pediatric cancer treatments. The presentation covers PEDMARK®, an FDA-approved medication to reduce hearing loss from cisplatin chemotherapy in pediatric patients, which launched in the U.S. in October 2022. The company has secured 7 years of U.S. market exclusivity and recently obtained EU and UK approvals with 10 years of E.U. exclusivity.